Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Completed 8Terminated 3Active not recruiting 3Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Melanoma 40Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 30Urinary Bladder Neoplasms 15Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Pancreatic Neoplasms 13Neoplasms 13Neoplasm Metastasis 13Ovarian Neoplasms 11Sarcoma 10Hodgkin Disease 10Glioblastoma 10Carcinoma, Transitional Cell 10Rectal Neoplasms 9Triple Negative Breast Neoplasms 8Prostatic Neoplasms 8Kidney Neoplasms 8Carcinoma, Hepatocellular 8Small Cell Lung Carcinoma 7Esophageal Neoplasms 7Colonic Neoplasms 7Breast Neoplasms 7Head and Neck Neoplasms 6Skin Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5

Interventions

durvalumab 7Bevacizumab 6tremelimumab 3Nivolumab 3lenvatinib 2fludarabine 2Cyclophosphamide 2zimberelimab 1toripalimab 1ropidoxuridine 1relatlimab 1pembrolizumab 1fludarabine phosphate 1atezolizumab 1X-Rays 1Technetium Tc 99m Aggregated Albumin 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radionuclide Imaging 1Platinum 1Photons 1Paclitaxel 1Observation 1Long-Term Potentiation 1Lidocaine 1Immunotherapy 1Immunoglobulin G 1IMC-001 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Liver Neoplasms × Nivolumab × Clear all
NCT03143270 2026-05-07

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
Gastrointestinal

Liver Neoplasms

NCT04658147 2025-12-18

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
31 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03383458 2025-11-21

CheckMate 9DX

Bristol-Myers Squibb

Phase 3 Active not recruiting
545 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡